Quality Outlook
03/05/2025
Bridget Doherty, MPH, MS; Silas Martin, MS; Tom Valuck, MD, JD
Johnson & Johnson’s research highlights the significant impact of the FDA’s Accelerated Approval Program, estimating that earlier access to cancer therapies has provided approximately 263 000 additional life years to patients, reinforcing the...
Johnson & Johnson’s research highlights the significant impact of the FDA’s Accelerated Approval Program, estimating that earlier access to cancer therapies has provided approximately 263 000 additional life years to patients, reinforcing the...
Johnson & Johnson’s research...
03/05/2025
Journal of Clinical Pathways